

# CareOregon Diabetes Treatment Pathway



**1<sup>st</sup> Line Oral Agents**  
\*No PA Required

Metformin  
Sulfonylurea  
Pioglitazone

**ASCVD, CKD, HF\***

Metformin  
Pioglitazone (ASCVD only)

\*These medications have been shown to improve health outcomes for people with DM + ASCVD, HF, and/or CKD.

**2<sup>nd</sup> Line Oral Agents**  
\*PA Required

DPP-4: Alogliptin  
SGLT-2: Steglatro

**PA Criteria:**  
1) Failure of metformin  
2) Failure of SU or pioglitazone  
3) A1c 7-10%

SGLT-2: Farxiga (PA required)

**1<sup>st</sup> Line Injections**  
\*No PA Required

Basal insulin: Basaglar  
Glargine-yfgn (generic Semglee)  
NPH  
Meal-time insulin: Admelog

GLP-1 agonist: Bydureon, Byetta, Trulicity, Victoza, Ozempic (PA required)

**2<sup>nd</sup> Line Injections**  
\*PA Required

GLP-1 agonist: Bydureon, Byetta, Trulicity, Victoza, Ozempic

**PA Criteria:**  
1) Failure of Metformin  
2) Failure of 2: SU, Pioglitazone, Alogliptin, Steglatro  
3) Failure of basal insulin or medical rationale to avoid  
4) A1c 7-10%  
Or Established ASCVD: Failure of SGLT-2

All patients should receive diabetes education

## Diabetes Medication Pearls

Metformin	Covered Agents	<b>Metformin</b>	Considerations: <ul style="list-style-type: none"> <li>• 1.5% A1C reduction</li> <li>• Low risk of hypoglycemia</li> <li>• Weight neutral</li> <li>• \$3/month</li> </ul>
	Dosing	500-2000 mg once or twice daily	
	How it works	Decrease amount of glucose produced by the liver, increases cells response to insulin Reduces appetite	
	Side effects	Gas, nausea, diarrhea	
Sulfonylureas	Covered Agents	<b>Glimepiride, Glipizide, Glyburide</b>	Considerations: <ul style="list-style-type: none"> <li>• 1.2% A1C Reduction</li> <li>• \$5/month</li> </ul>
	Dosing	Varying doses once or twice daily	
	How it works	Increases insulin secretion	
	Side effects	Risk for hypoglycemia, weight gain	
TZDs	Covered Agents	<b>Pioglitazone</b>	Considerations: <ul style="list-style-type: none"> <li>• 1% A1C reduction</li> <li>• Low risk of hypoglycemia</li> <li>• CV benefit</li> <li>• \$10/month</li> </ul>
	Dosing	15-45 mg once daily	
	How it works	Increases cells response to insulin (requires presence of insulin for its action)	
	Side effects	Weight gain, fluid retention, risk of worsening heart failure, may increase risk of bladder cancer	
Insulin	Covered Basal Insulin	<b>Basaglar, Glargine-yfgn, Novolin N, Humulin N</b>	Considerations: <ul style="list-style-type: none"> <li>• Highest A1C reduction, (variable)</li> <li>• ~\$200-400/month</li> <li>• Vials and pens covered</li> </ul>
	Covered Bolus Insulin	<b>Admelog, Novolin R, Humulin R</b>	
	Dosing	Basal: 10 units/day or 0.1-0.2 units/kg/day, then titrate to FBG target Bolus: 4 units, 0.1 units/kg, or 10% of basal dose before largest meal	
	Side effects	Hypoglycemia, weight gain	
DPP-4 inhibitors	Covered Agents	<b>Alogliptin</b>	Considerations: <b>PA REQUIRED</b> <ul style="list-style-type: none"> <li>• 0.7% A1C reduction</li> <li>• Low risk of hypoglycemia</li> <li>• Weight neutral</li> <li>• ~\$200/month</li> </ul>
	Dosing	25 mg once daily	
	How it works	Increases insulin production during meals, decreases amount of glucose produced by liver	
	Side effects	Risk of new or worsening heart failure	
SGLT-2 Inhibitors	Covered Agents	<b>Steglatro<sup>®</sup>, Farxiga<sup>®</sup></b>	Considerations: <b>PA REQUIRED</b> <ul style="list-style-type: none"> <li>• 0.7-1% A1C reduction</li> <li>• Steglatro preferred SGLT2</li> <li>• Farxiga with HF, CKD, ASCVD benefits*</li> <li>• Steglatro ~\$300/month</li> <li>• Farxiga ~\$500/month</li> </ul>
	Dosing	5-15 mg once daily (Steglatro <sup>®</sup> ) 5-10 mg once daily (Farxiga <sup>®</sup> )	
	How it works	Increases amount of glucose excreted in the urine	
	Side effects	Weight loss (initially), dizziness/low blood pressure, increased risk of urinary tract and genital mycotic infections	
GLP-1 agonists	Covered Agents	<b>Trulicity<sup>®</sup>, Bydureon<sup>®</sup>, Byetta<sup>®</sup>, Victoza<sup>®</sup>, Adlyxin<sup>®</sup>, Ozempic<sup>®</sup></b>	Considerations: <b>PA REQUIRED</b> <ul style="list-style-type: none"> <li>• 1% A1C reduction</li> <li>• Low risk of hypoglycemia</li> <li>• Trulicity<sup>®</sup>, Victoza<sup>®</sup>, Ozempic<sup>®</sup> with ASCVD benefits*</li> <li>• ~\$900/month</li> </ul>
	Dosing	Inject under the skin once daily (Victoza <sup>®</sup> , Adlyxin <sup>®</sup> ), twice daily (Byetta <sup>®</sup> ) or once weekly (Bydureon <sup>®</sup> , Trulicity <sup>®</sup> , Ozempic <sup>®</sup> )	
	How it works	Increases insulin secretion, decreases release of stored glucose, decreases appetite	
	Side effects	Weight loss, nausea, vomiting, satiety, injection site reactions, rare pancreatitis	

\*Studies have failed to show an improvement in patients at high risk of ASCVD despite guideline support.

